VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon May 21, 2024 7:52am

101 Views

Post# 36049524

Ventripoint: The New Standard in Cardiac Imaging

nice to see

APEC Portugal Report

Ventripoint Diagnostics Ltd. Shines as the Star of the Show as the World’s Top Cardiologists Meet in Portugal

What an exhilarating experience at AEPC 2024! We are immensely proud to have showcased our advanced AI-powered heart-scanning software, VMS+4.0, which became the talk of the conference attended by more than 16,000 heart care experts. Thank you to everyone who joined us in Porto, Portugal for your enthusiasm and engaging discussions.

Key Takeaways from AEPC 2024 from Bart Hendriks, our Strategic Partnerships Executive:

VMS Strain And Heat Maps

Our demonstrations highlighted how VMS+4.0’s visualization tools, especially the strain and heat maps, provide unparalleled insights into heart function. Cardiologists from around the globe were impressed by the precision and detail our software brings to cardiac diagnostics.

Automated Plotting Of Key Anatomical Landmarks

Attendees experienced firsthand how VMS+4.0 simplifies and enhances cardiac assessments. The elimination of manual plotting not only streamlines the diagnostic process but also increases accuracy and reliability in volumetric measurements.

The feedback has been overwhelmingly positive, reinforcing our belief that VMS+4.0 will revolutionize cardiac care by making advanced diagnostics quicker and more accessible.

Moving Forward

As we continue to await FDA approval, our resolve to deliver VMS+4.0 to healthcare providers worldwide has only strengthened. The interest and inquiries from international cardiologists and healthcare institutions at AEPC have been inspiring.

Ventripoint: The New Standard in Cardiac Imaging

With VMS+4.0, we’re not just following trends – we’re setting them. Our technology stood out as a beacon of innovation and practicality, proving that we are at the forefront of medical technology.

Thank you again for making us the star of AEPC 2024! We look forward to bringing our cutting-edge solutions to your hospitals and clinics.

Sincerely, Bart.

https://ventripoint.com/investors/apec-report/

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 3, 2024